Access Biotechnology

BioCentury’s weekly Public Equity Report also includes financings by Crinetics, Scholar Rock, Immatics, Inhibikase and Vicore

Also in BioCentury’s weekly Public Equity Report: Ascendis follows up a data release with a $300M offering; BioAge proposes terms for listing

Plus: Abata draws strategic investment from BMS as it preps first human study in multiple sclerosis

Few deals amid selloff, fears of volatility

Plus: Flagship-backed Abiologics launches; and rounds for GRO, Autobahn and Rona

Versant-founded immunology play launches with $168M to create biologics targeted to specific cell types

Largest upfront M&A payment for a preclinical biotech in three years 

Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura

Plus: U.K. rejoins Horizon Europe and more from Mariana, Corteria, Noetik, CymaBay, J&J, Alnylam and BlueWhale

San Diego company’s STAT6 program is partnered with Sanofi